

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5-US-WO	Int'l Appln No: PCT/GB03/003801
	Applicant: Alan Crossman et al.	
	Filing Date: March 20, 2009	Group Art Unit: 3221

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,322,346	03/1982	Korosi et al.			
	4,452,808	06/1984	Gallagher, Jr.			
	4,513,006	04/1985	Maryanoff et al.			
	4,582,916	04/1986	Maryanoff et al.			
	4,824,860	04/1989	Owen			
	6,200,970	03/2001	Ling et al.			
	6,420,369	07/2002	Marcotte			
	6,559,293	05/2003	Almarsson et al.			
	6,583,172	06/2003	Shank			
	6,649,607	11/2003	Leventer et al.			
FOREIGN PATENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	0138441	08/1988	EP			
	0900568	03/1999	EP			
	99/06408	02/1999	WO			
	01/04122	01/2001	WO			
	02/088096	11/2002	WO			
	02/094189	11/2002	WO			
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Beers et al., "The Merck Manual of Diagnosis and Therapy, 17th Edition", 1999, Merck Research Laboratories Whitehouse Station, NJ, pp. 1462-1473, XP002267011.				
		Beloborodova et al., "Method of Treatment of Hypertension-Hyperkinetic form of Dyskinesia of Biliferous Ways in Young Persons", 12/27/02, Abstract, XP002266976.				
		Blanchet et al., "Differing Effects of N-Methyl-D-Aspartate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-Phenyl-Tetrahydropyridine Monkeys," JPET, vol. 290, no. 3, 1999, pp. 1034-1040.				
		Brochie et al., "The Effects of Tolisopam on the Actions Induced by L-DOPA Administration in the MPTP - Lesioned Non-Human Primate Model of Parkinson's Disease", Society for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Program No. 165.18, pp. 1-2, XP008026196.				
		Burne et al., "The Contribution of Tremor Studies to Diagnosis of Parkinsonian and Essential Tremor: A Statistical Evaluation," Journal of Clinical Neuroscience, vol. 9, no. 3, 2002, pp. 237-242.				
		Connor, "A Double-Blind Placebo-Controlled Trial of Topiramate Treatment for Essential Tremor," Neurology, 59, 2002, pp. 132-134.				
		Fox et al., "Neural Mechanisms Underlying Peak-Dose Dyskinesia Induced by Levodopa and Apomorphine are Distinct: Evidence from the Effects of the Alpha ₂ Adrenoceptor Antagonist Idazoxan," Movement Disorders, vol. 16, no. 4, 2001, pp. 642-650.				
EXAMINER:	/Sahar Javanmard/			DATE CONSIDERED: 11/20/2009		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.						

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5-US-WO		Int'l Appln No: PCT/GB03/003801
	Applicant: Alan Crossman et al.		
	Filing Date: March 20, 2009	Group Art Unit: 3221	

	Henry et al., "μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease," <i>Experimental Neurology</i> , 171, 2001, pp. 139-146.
	Kanda et al., "Combined Use of the Adenosine A _{2A} Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity by Not Dyskinesia in MPTP-Treated Monkeys," <i>Experimental Neurology</i> , 162, 2000, pp. 321-327.
	Konitsiotis et al., "AMPA Receptor Blockade Improves Levodopa-Induced Dyskinesia in MPTO Monkeys," <i>Neurology</i> , Vol. 54, No. 8, April 25, 2000, pp. 1589-1595, XP008026187.
	Levine, "Medical Treatment of Essential Tremor and Parkinson's Disease," <i>Geriatrics</i> , vol. 53, issue 5, May 1998, 10 pages.
	Nash et al., "Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease," <i>Experimental Neurology</i> , 165, 2000, pp. 136-142.
	Revutsky et al., "Prophylaxis of Metcopathological Reactions in Patients with Ischemic heart Disease and Neurocirculatory Dystonia", <i>Vrachebnoe Delo</i> 1988 Russia, No. 2, 1988, pp. 7-10, XP008026189.
	Skradski et al., "Topiramate Blocks Kainate-Evoke Cobolt Influx into Cultured Neurons," <i>Epilepsia</i> , 41 (Suppl. 1), 2000, pp. S45-S47.
	Solyom et al., "Non-Competitive AMPA Antagonists of 2,3-Benzodiazepin Type", <i>Current Pharmaceutical Design</i> 2002, Netherlands, Vol. 8, No. 10, 2002, pp. 913-939, XP008026188.
	Tarnawa et al., "2,3-Benzodiazepine AMPA Antagonists", <i>Restorative Neurology and Neuroscience</i> , 1998, Vol. 13, pp. 41-57, XP008026184.
	Wolters et al., "Parkinson's Disease," <i>Recent Advances in Pharmacotherapy, CMAJ</i> , vol. 140, March 1, 1989, pp. 507-513.
	Answers.com, dyskinesia, http://www.answers.com/topic/dyskinesia , printed 09/11/2008, 4 pages.

EXAMINER: /Sahar Javanmard/	DATE CONSIDERED: 11/20/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE